Warejko Jillian K, Hmiel S Paul
St. Louis Children's Hospital, Saint Louis, MO, USA.
Pediatr Transplant. 2014 Dec;18(8):816-21. doi: 10.1111/petr.12374. Epub 2014 Oct 14.
Our center has offered thymoglobulin induction with steroid minimization to our pediatric renal transplant patients for the last 10 yr. Steroid minimization or avoidance has shown favorable results in survival, kidney function, and growth in previous studies of pediatric patients. We report our experience with this protocol over the past 10 yr with respect to patient/graft survival, acute rejection episodes, renal function, linear growth, bone density, cardiovascular risk factors, and opportunistic infections. A retrospective chart review was performed for pediatric renal transplant patients on the steroid-minimized protocol between January 2002 and December 2011 on an intention to treat basis. Patient demographics, height, weight, serum creatinine, iGFR, biopsies, and survival data were collected. Height and weight z-scores were calculated with EpiInfo 7, using the CDC 2000 growth charts. Survival was calculated using Kaplan-Meier analysis. eGFR was calculated using the original and modified Schwartz equations. Forty-four pediatric patients were identified, aged 13 months to 19 yr. Five-yr survival was 95.5% for males and 94.4% for females. Only five patients had biopsy-proven ACR, two of which were at more than 12 months post-transplantation. Height delta z-scores from transplant to one, three, and five yr were 0.34, 0.38, and 0.79, respectively. Weight delta z-scores from transplant to one, three, and five yr were 0.87, 0.79, and 0.84, respectively. Mean original Schwartz eGFR was 84.3 ± 15.8 mL/min/1.73 m(2) , modified Schwartz eGFR was 59.3 ± 11.5 mL/min/1.73 m(2) , and iGFR was 64.2 ± 8.5 mL/min/1.73 m(2) at three yr. Of 18 subjects who had a bone density exam, none had a z-score less than -2 on DEXA exam at one-yr post-transplantation. Fifty-one percent of patients were on antihypertensives at the time of transplant compared with 43% at one-yr post-transplantation. Three yr post-transplantation, the average LDL was <100 mg/dL, and average total cholesterol was <200 mg/dL. There were no clinical episodes of EBV or CMV infection. A steroid-minimized protocol with thymoglobulin induction is safe and provides favorable improvement in linear growth, stable graft function, stable or improved cardiovascular risk factors, and normal bone density in pediatric renal transplant patients.
在过去10年里,我们中心为小儿肾移植患者提供了使用最低剂量类固醇的抗胸腺细胞球蛋白诱导治疗方案。在之前针对小儿患者的研究中,最低剂量类固醇或避免使用类固醇在患者生存率、肾功能和生长发育方面均显示出良好效果。我们报告了过去10年里采用该方案在患者/移植物存活、急性排斥反应、肾功能、线性生长、骨密度、心血管危险因素和机会性感染方面的经验。对2002年1月至2011年12月期间接受最低剂量类固醇方案治疗的小儿肾移植患者进行了回顾性图表审查,采用意向性治疗分析。收集了患者人口统计学资料、身高、体重、血清肌酐、估算肾小球滤过率(iGFR)、活检结果和存活数据。使用EpiInfo 7软件,根据美国疾病控制与预防中心2000年生长图表计算身高和体重z评分。采用Kaplan-Meier分析计算生存率。使用原始和改良的施瓦茨方程计算估算肾小球滤过率(eGFR)。共确定了44例小儿患者,年龄在13个月至19岁之间。男性5年生存率为95.5%,女性为94.4%。只有5例患者经活检证实发生急性细胞排斥反应(ACR),其中2例发生在移植后12个月以上。从移植到1年、3年和5年的身高z评分变化分别为0.34、0.38和0.79。从移植到1年、3年和5年的体重z评分变化分别为0.87、0.79和0.84。移植后3年,原始施瓦茨eGFR的平均值为84.3±15.8 mL/min/1.73m²,改良施瓦茨eGFR为59.3±11.5 mL/min/1.73m²,iGFR为64.2±8.5 mL/min/1.73m²。在18例接受骨密度检查的受试者中,移植后1年时,双能X线吸收法(DEXA)检查中无一人的z评分低于-2。移植时51%的患者服用抗高血压药物,移植后1年时这一比例为43%。移植后3年,平均低密度脂蛋白(LDL)<100 mg/dL,平均总胆固醇<200 mg/dL。没有发生EB病毒(EBV)或巨细胞病毒(CMV)感染的临床病例。采用抗胸腺细胞球蛋白诱导的最低剂量类固醇方案是安全的,并且在小儿肾移植患者的线性生长、稳定的移植物功能、稳定或改善的心血管危险因素以及正常骨密度方面提供了良好的改善。